Archive for the ‘Latest Research’ Category
Nightstar Receives U.S. and European Orphan Drug Designation for Gene Therapy to Treat Choroideremia
March 24th, 2015 by Cory MacDonald
PRESS RELEASE: London, 11 January 2015 – NightstaRx Ltd (“Nightstar”), the biopharmaceutical company specialising in bringing therapies for retinal dystrophies
Spark Therapeutics, the Philadelphia firm specializing in gene therapy treatments who just last week announced the start of the United States first
January 20th, 2015 by Danny Boren
Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating, genetic diseases, announced today it has initiated a Phase
What is the Argus II? The Argus® II Retinal Prosthesis System (“Argus II”) is also known as the bionic eye
More than 25 leading retinal researchers from around the World joined together June 17 & 18 in Denver, Colorado for the 2nd International Science Symposium for Choroideremia.
Oxford University issues press release reporting on its 6-month results from the first ever Gene Therapy Trial for Choroideremia
Researchers at John Hopkins University succeed in generating three dimensional retinal tissue from iPS cells.
Surgeons in Oxford have used a gene therapy technique to improve the vision of six patients who would otherwise have
CBS News Coverage of Oxford Gene Therapy Trials for Choroideremia.
2009 Press Release by The Children’s Hospital of Philadelphia about Dr. Jean Bennett, Dr. Katherine High & Dr. Al McGuire’s work on Leber’s Congenital Amaurosis (LCA). These groundbreaking results are paving the way for a similar study at CHOP to treat Choroideremia.